When biotech company Insilico Medicine announced that its generative AI platform had "discovered" a promising drug candidate for pulmonary fibrosis, it highlighted an emerging regulatory blind spot. The company's enthusiastic press release exemplifies a growing trend: as AI systems play larger roles in scientific discovery, questions about proper attribution have become urgent. Currently, no standardized framework exists for determining whether AI systems should receive credit as inventors or discoverers, raising complex questions about patents, publications, and professional recognition that extend far beyond this single announcement.
The significance extends beyond academic credit allocation. If AI systems are credited as discoverers, questions arise about liability, regulatory approval chains, and reproducibility standards. Regulatory bodies like the FDA must eventually clarify whether drug candidates discovered by AI undergo different approval pathways, and whether transparency about AI involvement in development influences how regulators evaluate efficacy and safety data. These decisions will shape how pharmaceutical companies structure their research programs and whether investors view AI-discovered drugs differently from traditionally developed ones.
The lack of policy clarity comes at a critical moment as AI accelerates drug discovery cycles. Without established guidelines, companies may make inconsistent attribution claims that confuse investors, regulators, and the scientific community. Policymakers across multiple jurisdictions—from patent offices to health regulatory agencies—need to develop coordinated standards defining when and how to credit AI systems, what transparency requirements apply, and how this affects intellectual property rights and scientific accountability in an increasingly AI-driven research landscape.
This attribution question represents a broader challenge facing AI policy: existing regulatory frameworks assumed human decision-makers at every stage, but AI's role in scientific processes now demands fundamental reconsideration of how responsibility, credit, and accountability are assigned in collaborative human-AI research environments.